Press Releases
Flamel Technologies Announces New Nominees for the Board of Directors
Lyon, France, May 8, 2003 – Flamel Technologies S.A. (NASDAQ: FLML) today announced its candidates for election to its Board of Directors for the year 2003-2004.
The proposed candidates include three new directors:
Raul Cesan, who served until 2001 as President and Chief Operating Officer of Schering Plough Corporation, a major worldwide pharmaceutical company. He currently serves on a number of boards of directors including those of First Health Group Corporation, a $2.5 billion provider of health benefits, and The New York Times Company, a media company.
William D. Dearstyne, who served until 2002 as Company Group Chairman of Johnson & Johnson, a major worldwide pharmaceutical company.
Michel Greco, who served until 2003 as directeur general delegue and member of the Board of Directors of Aventis Pasteur, a major French pharmaceutical company.
Also standing for election are Jean-Noel Treilles, President of the Ethical division of E.Merck, and former president and chief executive officer of Merck-Lipha France, Gerard Soula, president and ceo of Flamel, and Stephen Willard, executive vice president and chief financial officer of the Company.
"We are delighted to present senior pharmaceutical executives of such distinction as board candidates to the next general assembly of Flamel," said Gerard Soula, president and chief executive officer of Flamel Technologies. "I feel these highly-qualified individuals will make major contributions to Flamel and help us to continue to build a leading drug delivery company."
Flamel Technologies S.A. is a biopharmaceutical company principally engaged in the development of two unique polymer-based delivery technologies for medical applications. Flamel’s Medusa® nano-encapsulation technology is designed to deliver therapeutic proteins. Micropump® is a controlled release technology for the oral administration of small molecule drugs. Flamel’s expertise in polymer science has also been instrumental in the development of a photochromic eyeglass lens product now marketed by Corning Inc. Additionally, Flamel has developed new herbicide delivery systems now being tested by Monsanto and has patented a biomaterial, ColCys™.
This document contains a number of matters, particularly as related to the status of various research projects and technology platforms, that constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The presentation reflects the current view of management with respect to future events and is subject to risks and uncertainties that could cause actual results to differ materially from those contemplated in such forward-looking statements. These risks include risks that products in the development stage may not achieve scientific objectives or milestones or meet stringent regulatory requirements, uncertainties regarding market acceptance of products in development, the impact of competitive products and pricing, and the risks associated with Flamel’s reliance on outside parties and key strategic alliances. These and other risks are described more fully in Flamel’s Annual Report on the Securities and Exchange Commission Form 20-F for the year ended December 31, 2001.
